scispace - formally typeset
Search or ask a question
Institution

Mayo Clinic

HealthcareRochester, Minnesota, United States
About: Mayo Clinic is a healthcare organization based out in Rochester, Minnesota, United States. It is known for research contribution in the topics: Population & Transplantation. The organization has 63387 authors who have published 169578 publications receiving 8114006 citations.


Papers
More filters
Journal ArticleDOI
21 Dec 2000-Nature
TL;DR: It is shown that vaccination with Aβ protects transgenic mice from the learning and age-related memory deficits that normally occur in this mouse model for Alzheimer's disease and may prevent and, possibly, treat Alzheimer's dementia.
Abstract: Vaccinations with amyloid-beta peptide (A beta) can dramatically reduce amyloid deposition in a transgenic mouse model of Alzheimer's disease. To determine if the vaccinations had deleterious or beneficial functional consequences, we tested eight months of A beta vaccination in a different transgenic model for Alzheimer's disease in which mice develop learning deficits as amyloid accumulates. Here we show that vaccination with A beta protects transgenic mice from the learning and age-related memory deficits that normally occur in this mouse model for Alzheimer's disease. During testing for potential deleterious effects of the vaccine, all mice performed superbly on the radial-arm water-maze test of working memory. Later, at an age when untreated transgenic mice show memory deficits, the A beta-vaccinated transgenic mice showed cognitive performance superior to that of the control transgenic mice and, ultimately, performed as well as nontransgenic mice. The A beta-vaccinated mice also had a partial reduction in amyloid burden at the end of the study. This therapeutic approach may thus prevent and, possibly, treat Alzheimer's dementia.

1,580 citations

Journal ArticleDOI
TL;DR: Adalimumab was superior to placebo for induction of remission in patients with moderate to severe Crohn's disease naive to anti-TNF therapy and was well tolerated.

1,579 citations

Journal ArticleDOI
TL;DR: Atezolizumab showed encouraging durable response rates, survival, and tolerability, supporting its therapeutic use in untreated metastatic urothelial cancer.

1,578 citations

Journal ArticleDOI
TL;DR: There is no universal agreement on the definition of anaphylaxis or the criteria for diagnosis, so representatives from 16 different organizations or government bodies, including representatives from North America, Europe, and Australia, to continue working toward a universally accepted definition.
Abstract: There is no universal agreement on the definition of anaphylaxis or the criteria for diagnosis. In July 2005, the National Institute of Allergy and Infectious Disease and Food Allergy and Anaphylaxis Network convened a second meeting on anaphylaxis, which included representatives from 16 different organizations or government bodies, including representatives from North America, Europe, and Australia, to continue working toward a universally accepted definition of anaphylaxis, establish clinical criteria that would accurately identify cases of anaphylaxis with high precision, further review the evidence on the most appropriate management of anaphylaxis, and outline the research needs in this area.

1,572 citations

Journal ArticleDOI
TL;DR: The utility of structural imaging and other markers will be increased by standardization of acquisition and analysis methods, and by development of robust algorithms for automated assessment, as well as by research into other imaging and nonimaging markers.
Abstract: Structural imaging based on magnetic resonance is an integral part of the clinical assessment of patients with suspected Alzheimer dementia. Prospective data on the natural history of change in structural markers from preclinical to overt stages of Alzheimer disease are radically changing how the disease is conceptualized, and will influence its future diagnosis and treatment. Atrophy of medial temporal structures is now considered to be a valid diagnostic marker at the mild cognitive impairment stage. Structural imaging is also included in diagnostic criteria for the most prevalent non-Alzheimer dementias, reflecting its value in differential diagnosis. In addition, rates of whole-brain and hippocampal atrophy are sensitive markers of neurodegeneration, and are increasingly used as outcome measures in trials of potentially disease-modifying therapies. Large multicenter studies are currently investigating the value of other imaging and nonimaging markers as adjuncts to clinical assessment in diagnosis and monitoring of progression. The utility of structural imaging and other markers will be increased by standardization of acquisition and analysis methods, and by development of robust algorithms for automated assessment.

1,572 citations


Authors

Showing all 64325 results

NameH-indexPapersCitations
Eugene Braunwald2301711264576
Peter Libby211932182724
Cyrus Cooper2041869206782
Rob Knight2011061253207
Robert M. Califf1961561167961
Eric J. Topol1931373151025
Dennis W. Dickson1911243148488
Gordon B. Mills1871273186451
Julie E. Buring186950132967
Patrick W. Serruys1862427173210
Cornelia M. van Duijn1831030146009
Paul G. Richardson1831533155912
John C. Morris1831441168413
Valentin Fuster1791462185164
Ronald C. Petersen1781091153067
Network Information
Related Institutions (5)
Brigham and Women's Hospital
110.5K papers, 6.8M citations

98% related

Cleveland Clinic
79.3K papers, 3.4M citations

98% related

Icahn School of Medicine at Mount Sinai
76K papers, 3.7M citations

97% related

Johns Hopkins University School of Medicine
79.2K papers, 4.7M citations

96% related

University of Alabama at Birmingham
86.7K papers, 3.9M citations

96% related

Performance
Metrics
No. of papers from the Institution in previous years
YearPapers
2023268
20221,216
202112,779
202011,352
201910,004
20188,870